Rein Therapeutics
Open
$1.36
Prev. Close
$1.36
High
$1.36
Low
$1.36
Market Snapshot
$33.52M
-0.7
-3.78
10
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 11 full-time employees. The company went IPO on 2017-06-29. The firm's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
emptyResult
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 11 full-time employees. The company went IPO on 2017-06-29. The firm's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
Recently from Cashu
Please provide the content you would like me to summarize.
Please provide the text you would like summarized, and I'll be happy to help!
Please provide the text you would like summarized, and I'll be happy to help!
Please provide the text you would like summarized, and I'll be happy to help!
Rein Therapeutics: Leading Innovation in Biopharmaceuticals with Strategic Drug Development
Rein Therapeutics: Spotlight on Strategic Developments in Drug Innovation Rein Therapeutics is currently at the forefront of innovation in the biopharmaceutical industry, particularly in the developme…
Rein Therapeutics: Pioneering Biopharmaceutical Innovations for Oncology and Neurological Disorders
Rein Therapeutics: A Growing Force in Biopharmaceutical Innovation Rein Therapeutics is currently at the forefront of biopharmaceutical development, showcasing a commitment to advancing therapies that…